Aprea Therapeutics Inc (APRE) has issued an announcement.
Aprea Therapeutics, Inc. has struck a deal with investors for a significant financial boost, agreeing to sell over 1.6 million shares and various tranches of warrants, potentially raking in gross proceeds of around $16 million initially and possibly an additional $18 million in the future. This transaction, set to close on March 13, 2024, hinges on standard closing conditions. The company is also ensuring the resale of these securities by filing the necessary registration statements. In a related move, Aprea terminated a previous sales agreement and announced FDA clearance for a new drug, signaling strategic shifts and progress in its pipeline.
For a thorough assessment of APRE stock, go to TipRanks’ Stock Analysis page.
